

# INPLASY PROTOCOL

To cite: Wang et al. Sodium glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis. Inplasy protocol 2022110095. doi: 10.37766/inplasy2022.11.0095

Received: 19 November 2022

Published: 19 November 2022

**Corresponding authors:**  
Yu Geng and Ping Zhang

gya02137@btch.edu.cn

zhpdoc@126.com

**Author Affiliation:**  
Department of Cardiology,  
Beijing Tsinghua Changgung  
Hospital, School of Clinical  
Medicine, Tsinghua University,  
Beijing, China.

**Support:** None.

**Review Stage at time of this submission:** Data analysis.

**Conflicts of interest:**  
None declared.

## Sodium glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis

Wang, YT<sup>1</sup>; Gao, T<sup>2</sup>; Meng, C<sup>3</sup>; Li, SY<sup>4</sup>; Bi, L<sup>5</sup>; Geng, Y<sup>6</sup>; Zhang, P<sup>7</sup>.

**Review question / Objective:** We sought to conduct a systematic review and meta-analysis to evaluate safety and effectiveness of Sodium glucose co-transporter 2 inhibitors.  
**Condition being studied:** Cardiovascular death, heart failure hospitalization, all-cause death.

**Information sources:** We will search the references in the included trials and personal files. We will request advice from experts in the field. In addition, we will search associated articles from meetings, and contacted the authors of included trials, if need.

**INPLASY registration number:** This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 19 November 2022 and was last updated on 19 November 2022 (registration number INPLASY2022110095).

\*Yintang Wang, Tong Gao and Chang Meng have contributed equally to this work

### INTRODUCTION

**Review question / Objective:** We sought to conduct a systematic review and meta-analysis to evaluate safety and

effectiveness of Sodium glucose co-transporter 2 inhibitors.

**Condition being studied:** Cardiovascular death, heart failure hospitalization, all-cause death.

---

## METHODS

**Participant or population:** Heart failure with mildly reduced or preserved ejection fraction.

**Intervention:** Heart failure with mildly reduced or preserved ejection fraction.

**Comparator:** Placebo.

**Study designs to be included:** The search strategy was RCTs.

**Eligibility criteria:** (1) Heart failure with mildly reduced or preserved ejection fraction. (2) treatment with Sodium glucose co-transporter 2 inhibitors. (3) outcomes Indicators: cardiovascular death, heart failure hospitalization, including one.

**Information sources:** We will search the references in the included trials and personal files. We will request advice from experts in the field. In addition, we will search associated articles from meetings, and contacted the authors of included trials, if need.

**Main outcome(s):** Cardiovascular death, heart failure hospitalization, all-cause death.

**Quality assessment / Risk of bias analysis:** We evaluated the methodological quality of the individual studies using the Cochrane risk of bias tool for RCTs.

**Strategy of data synthesis:** We will consider using the number of participants and deaths between different groups for analysis. Mortality may also be reported.

**Subgroup analysis:** Subgroup analysis was performed on HFmrEF and HFpEF.

**Sensitivity analysis:** We conducted sensitivity analyses to investigate the influence of a single study on the overall pooled estimate of each predefined outcome.

**Country(ies) involved:** China.

**Keywords:** Sodium glucose co-transporter 2 inhibitors; Heart failure with preserved ejection fraction; Heart failure with mildly reduced ejection fraction.

### Contributions of each author:

Author 1 - Yintang Wang.

Author 2 - Tong Gao.

Author 3 - Chang Meng.

Author 4 - Siyuan Li.

Author 5 - Lei Bi.

Author 6 - Yu Geng.

Email: gya02137@btch.edu.cn

Author 7 - Ping Zhang.

Email:zhpdoc@126.com